Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04624204 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

StatusActive, Not Recruiting
PhasePhase 3
Started2020-12-08
View on ClinicalTrials.gov ↗
Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.

Amendment history 1 change detected by DataLookout

2026-09-11
Primary endpoint(s) modified
WasOverall Survival: the time from randomization to death due to any cause, Progression-free Survival Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); the time from randomization to progression or death due to any cause, whichever occurs first
NowOverall Survival: the time from randomization to death due to any cause
Trial Details
NCT Number NCT04624204
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Small Cell Lung Cancer
Enrollment 672 participants
Start Date 2020-12-08
Primary Completion 2027-10-28 (estimated)
Study Completion 2027-10-28 (estimated)
Updated on ClinicalTrials.gov 2026-09-10